Key result
DOACs appear safer and potentially more effective than VKAs for AF in hemodialysis patients.
Why the study?
An optimal strategy for managing thrombotic risk in patients with AF receiving hemodialysis remains uncertain, and definitive benefit from oral anticoagulants has not been demonstrated.
Do direct oral anticoagulants improve safety and efficacy compared to vitamin K antagonists in patients with atrial fibrillation receiving hemodialysis?
Do direct oral anticoagulants improve safety and efficacy compared to vitamin K antagonists in patients with atrial fibrillation receiving hemodialysis?
This review highlights that DOACs may offer a safer and potentially more effective alternative to vitamin K antagonists for managing AF in hemodialysis patients, though better risk prediction tools and dosing strategies are needed.
No takes yet. Share an insight, caveat, or question.
Optimal anticoagulation for AF on HD lacks proven benefit and may increase harm; leaves open strategy pending dedicated trials.
Kohn et al. (2026) conducted a review in Atrial fibrillation in patients receiving hemodialysis. Direct oral anticoagulants vs. Vitamin K antagonists was evaluated. Direct oral anticoagulants appear safer and possibly more effective than vitamin K antagonists for managing atrial fibrillation in patients receiving hemodialysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: